Neurogene (NGNE) Other Operating Expenses (2013 - 2019)

Neurogene (NGNE) posted Other Operating Expenses of $47.7 million for Q3 2019, up 3534618.52% on a QoQ basis from -$1350.0 in Q3 2014.

Neurogene (NGNE) Other Operating Expenses (2013 - 2019) Analysis & Trends

Neurogene's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $47.7 million for Q3 2019.

Quarterly Other Operating Expenses changed N/A year-over-year to $47.7 million in Q3 2019, while the trailing twelve-month figure through Jun 2020 was $47.7 million (changed N/A YoY) and the FY2019 annual result came in at $47.7 million, changed N/A from the prior year.
Other Operating Expenses was $47.7 million for Q3 2019 at Neurogene, up from -$1350.0 in the prior quarter.
Across five years, Other Operating Expenses topped out at $47.7 million in Q3 2019 and bottomed at $47.7 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Neurogene	776.69 Mn	776.69 Mn	-

Download Data